A Phase III Trial to Evaluate the Efficacy and Safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Latest Information Update: 09 Feb 2026
At a glance
- Drugs JSKN 003 (Primary) ; Fruquintinib; Regorafenib; Tipiracil/trifluridine
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai JMT-BIO Technology
Most Recent Events
- 09 Feb 2026 New trial record